Formulation and Evaluation of pH-Responsive Eudragit L100-Coated Amoxicillin-Clavulanate Matrix Tablets for Colonic Delivery
Pratikshya Panda, Gauri, Anju Mishra, Sita Ahirwar
Students, School of Pharmacy, Chouksey Engineering College, Bilaspur (CG) India.
*Corresponding Author E-mail: anishc@cecbilaspur.ac.in
ABSTRACT:
Formulation process of a colon-targeting antibiotic tablet was developed by amoxicillin/clavulanate (AC) in hydrophilic matrix polymer and film coating with pH-sensitive Eudragit L100. The aim of this approach was to reduce drug release in the stomach and small intestine while allowing fast release in colon (pH ≥7). The tablets were made using a direct compression method by taking guar gum as a matrix polymer and film coating with Eudragit L100. The pre-formulation studies (melting point, UV-IR spectra, calibration curves) identified the drug and determined the λmax to be ~228 nm. The results of coated tablets showed limited release amounts of the drug (<10%) in the simulated gastric (pH 1.2) and intestinal fluids (pH 6.8) and around 80% release of AC after transferring the sample into pH 7.2 fluid. The release mechanism of the coated tablet followed Higuchi diffusion model that represents some combination of swelling/erosion of matrix. The tablets showed qualified parameters from the tablet making point of view (weight uniformity, hardness ~5-6 kg, friability <1% and drug content ~100%). Stability studies were done on the tablets (40°C/75% RH for three months) and did not show significant changes in drug content or in release behavior.
KEYWORDS: Formulation, Evaluation, Matrix.
INTRODUCTION:
Colon-related medication delivery can improve the effectiveness of treatment for colon-related illnesses (such as diverticulitis, inflammatory bowel disease) as it releases medication at the infection site and causes less systemic side effects1. Latest evidence points to the local delivery of the medication in the inflamed segment of the colon for better efficacy. Amoxicillin-clavulanate is a widely used broad-spectrum β-lactam antibiotic in intra-abdominal and gastrointestinal infections2,3. An extended-release 1000mg/62.5mg formulation of co-amoxiclav has been made available for use (12-hour dosing), which proves the effectiveness of β-lactams that have been sustained-released. However, non-coated antibiotics are absorbed too fast in the gastrointestinal tract and may not attain the required high concentrations in the colon5-7.
Eudragit® polymers (methacrylic acid copolymers) play an important role in making enteric coatings. Eudragit L100 (methacrylic acid:methyl methacrylate 1:1) is insoluble at low pH but dissolves quickly at pH levels above7. For example, it has been demonstrated that Eudragit L100 films dissolve about 100 percent at pH 7.2 in an hour. Therefore, tablets covered with Eudragit L100 can shield the medicine in the stomach and let it go in the distal intestine8,9. Several combinations of Eudragit copolymers have been used in practice to provide the possibility to control the release: It is also indicated that Eudragit L100-55/S100 coatings on mesalamine-containing tablets permitted one to shift the drug release towards pH 5.5–7.0. In this study, the choice of Eudragit L100 was determined as a convenient pH-sensitive coating responsible for the targeted release of amoxicillin/clavulanate (AC) in the colon10,11.
Thus, hydrophilic matrix polymers can also play a significant role in the tuning of release. There are natural polysaccharides like guar gum that swell and decompose due to the presence of colonic bacteria; thus providing the microbial trigger for the running process12. For instance, matrix tablets with the presence of 20% of such polysaccharides are shown to remain intact in the upper part of the gastro-intestinal tract and erode in the colon. Besides, hydrophilic cellulose ethers (HPMC) may also be used as components of a gel matrix controlling the liquid penetration13-15. For example, in the study of colon targeting, the tablets with mesalamine covered with a mixture of Eudragit L100 and HPMC (E15 LV) demonstrated a delayed release until the moment when the drug was exposed to the pH of 7 and HPMC channels facilitated diffusion of drug16-18. In this respect, AC was loaded into hydrophilic matrices (in the form of guar gum) with outer Eudragit L100 coating to achieve their sequential pH- and microflora-dependent release. Thus, preformulation and characterization (melting point measurement, spectroscopy, and tablet evaluation), followed by in vitro release testing in simulated conditions, were carried out. In vitro methods were performed, using rat cecal content to replicate the conditions in the colon. Finally, accelerated stability studies have been conducted in order to investigate the robustness of the developed formulation.
Materials: Amoxicillin trihydrate (USP classification) and potassium clavulanate (of Ph. Eur grade) served as the model medications and were sourced from Dr. Reddy’s Laboratory in Hyderabad. Gaur gum was sourced from CDR located in Delhi. Microcrystalline cellulose, starch, and talc were sourced from Loba Chem Pvt. Ltd in Mumbai, while magnesium stearate was obtained from Moly Chem in Mumbai. All solvents and reagents were acquired from Merck in Germany, all of which were of analytical quality. All chemicals used in the study were pharmaceuticals or analytical grade and were received in their original forms.
The combined powder was prepared in a 4:1 weight ratio (amoxicillin: clavulanate). Guar gum (a type of polysaccharide) and HPMC E15 LV were selected as matrix formulation materials. Eudragit® L100 (a methacrylic acid-methyl methacrylate copolymer) was used for coating19. Other excipients included microcrystalline cellulose (as a diluent), starch paste (as a binder), talc and magnesium stearate (as lubricants).
Preformulation Studies: The first characterization of raw materials and blends consisted of the creation of the calibration curve, UV-visible and FT-IR spectroscopies, and determination of the pre-compression characteristics.
Preparation Calibration Curve of Mesalamine: To obtain a (1000µg/ml) standard stock solution, 100mg of the drug was weighed and diluted in 100ml of 0,1N HCl (pH=1.2) in a 100ml volumetric flask. A volume of 10 ml of stock solution (1) was added into another 100ml volumetric flask to obtain stock solution (2) with a concentration of (100µg/ml). Then, volumes of 1,2,3,4,5,6, and 7ml of the newly obtained stock solution (2) were placed into a 10ml volumetric flask to obtain final concentrations of 10,20,30,40,50,60, and 70µg/ml using 0,1N HCl (pH=1.2). The absorbance of the obtained standard solution was measured at a wavelength of 232.5 nm via UV/VIS spectrophotometer (UV-1700 Shimadzu). The linearity of the standard curve was evaluated using the determination of the square of the correlation coefficient (r2) using the method of least squares analysis20.
θ = tan – 1(h/r)
Powder weight
LBD = –––––––––––––––––––
volume of the packing
Powder weight
TBD = ––––––––––––––––––––––––
tapped volume of the packing
Compressibility Index: The compressibility index of particles was calculated using Carr’s compressibility index.
(TBD – LBD)
Carr’s index (%) = [ ––––––––––––––– ] × 100.
TBD
Hausner’s ratio indicates the ease of measurement of powder flow. The following formula was applied to determine the ratio.
Tapped density
Hausner’s ratio = –––––––––––––––
Bulk density
Preparation of the Matrix Tablets:
In preparing F1 to F5, tablets were prepared by direct compression. The active ingredient (amoxicillin: clavulanate) along with the polymer (Gaur gum) was milled in the mortar using a #40 sieve for about 10 min. After sieving with #40, lactose (the diluent) was mixed with the powder blend for the next 5 min after which the powder blend was further milled through the #60 sieve, lubricated with the requisite amount of magnesium stearate and talc. The resulting powder was directly compressed into tablets with the Rimek tablet mini press using 10 mm flat punches. The details of the formulation ingredients are given in Table 1.
Afterwards, Eudragit L100 coating solution was used to coat the medicated matrix tablets. Eudragit L100 coating solutions in concentrations of 5 percent, 10 percent, and 20 percent (w/v) were made by mixing ethanol, polyethylene glycol 400 (5 percent w/v), and water (1:1). Dip coating method was employed for the coating of the matrix tablets after immersing the tablets in the coating solution.
100
% Friability = (W1 – W2) × ––––––
W1
Here W1 is the weight of the ten tablets and W2 is the final weight of the ten tablets.
Friability values lesser than 0.5-1% are widely accepted.
Weight recording was done using a digital balance in order to find the weight (WI) of 20 tablets for each formulation. After determining the average weight (WA) of the tablets, the calculations for percentage weight variation were performed.
Table 1: Composition of Matrix Tablet of Mesalamine
|
S. No. |
Ingredients |
F1 |
F2 |
F3 |
F4 |
F5 |
|
1 |
amoxicillin: clavulanate (4:1) |
250 |
250 |
250 |
250 |
250 |
|
2 |
Gaur Gum |
75 |
50 |
37.5 |
25 |
12.5 |
|
3 |
Microcrystalline Cellulose |
22.5 |
47.5 |
60 |
73 |
85 |
|
4 |
Starch (10%) |
25 |
25 |
25 |
25 |
25 |
|
5 |
Talc |
5 |
5 |
5 |
5 |
5 |
|
6 |
Magnesium Stearate |
2.5 |
2.5 |
2.5 |
2.5 |
2.5 |
|
7 |
Total |
380 |
380 |
380 |
380 |
380 |
The active ingredient content was determined by grinding five tablets of each formulation using a mortar and pestle. From the resulting powder, an appropriate weight equivalent to 250mg of medicine was then diluted with phosphate-buffered saline (PBS) solution of pH 6.8 in a 100ml volumetric flask to make a diluted solution. The mixture was later filtered and sonicated for 60 minutes. Thereafter, a suitable quantity of the clear filtrate was diluted and analyzed spectrophotometrically at 331.60 nm against the blank. The process was followed three times, and the content of active ingredient was obtained.
The swelling index was also calculated as a percentage of weight gain of the tablet. Swelling property of different formulations was tested. A single tablet from each formulation was placed in a Petri dish containing 6.8 phosphate buffer. At the end of one hour, the tablet was taken out, dried using a tissue paper and weighed. The tablet was then weighed every 2 hours, and the process continued until 16 hours were completed. The percentage weight gain of tablet was determined using a formula.
(Mt-Mo)
S.I = { ––––––––– } × 100
Mo
Where, S.I = swelling index, Mt = weight of tablet at time 't', Mo = weight of tablet at time t = 0.
The USP Type I Apparatus (Paddle) was utilized to perform an in-vitro dissolution experiment in 0.1 N HCl at 100 rpm for 2 hours (900ml). The dissolution medium was switched to the pH 7.4 phosphate buffer (900ml) and the dissolution was carried out for 3 hours according to the average small intestinal transit time of 3 hours. The dissolution medium was again changed to pH 6.8 phosphate buffer after 5 hours and the dissolution continued for another 7 hours. At the end of this time period, 10 millilitres of the sample were withdrawn and analysed for the amoxicillin – clavulanate concentration. After every sample withdrawal, 10 millilitres of fresh and filtered dissolution medium (buffers) was added to maintain the volume.
Clavulanate and amoxicillin were reported to dissolve in ethanol and methanol where the solubility in water was said to be unlimited. The melting point of amoxicillin was measured to be around 194 °C. The decomposition temperature of clavulanate was over 160°C. The partition coefficient and weight loss of amoxicillin and clavulanate at a pH value of 7.2 was assessed to be equal to 11.7 and 8% respectively. The UV spectrophotometer (UV-1700 Shimadzu-Japan) was used to find the absorption band of amoxicillin at 273nm while clavulanate was shown to have negligible absorption at 228nm (Figure 1) in 0.1 N HCl, phosphate buffer (pH 6.8) and phosphate buffer (pH 7.4).
Figure 1: UV spectrum of Amoxicillin at 273nm and Clavulanate at 228 nm and Calibration curve of Amoxicillin at 273nm
One of the methods used to recognize Amoxicillin and clavulanate using FTIR spectrophotometer was to ascertain its compatibility with the co-factor components. According to the found data, the integrity of the drug was evaluated according to what was presented in the IR spectrum. The results of the FT-IR spectrum of substances and physical mixtures showed the presence of expected β-lactam and carbonyl bands (1760-1775 cm⁻ą) while no other peaks appear (Figure 2).
Figure 2: FT-IR spectra of a) Amoxicillin trihydrate, b) Potassium Clavulanate, c) Mixture of Amoxicillin trihydrate and Potassium Clavulanate, and d) Physical mixture
Different pre-compression parameters were used for the powder blend used in making tablets shown in Table No. 2. The angle of repose of the powder blend shows that it had desirable flow characteristics. The bulk density of each formulation ranged from 0.312 + 0.005 gm/ml to 0.348 + 0.016 gm/ml which showed that the powder blend possessed good flow properties. Each formulation also had tapped density of 0.502 + 0.007 gm/ml to 0.565 + 0.005 gm/ml representing excellent flow characteristics. The compressibility index of each formulation was found to be between 31.27 + 1.27 to 44.60 + 0.26 representing that the powder had good flow properties. The ratio of Hausser for each formulation was between 1.15 + 0.02 to 1.20 + 0.10 indicating good flow properties. Table 3 exhibits data regarding post-compression parameters including weight uniformity, hardness, thickness, friability, swelling index and disintegration time. All the tablets from different batches showed compliance with weight uniformity. The hardness of matrix tablets was found to be in the range of 50.08 – 6.60+ 0.21 kg/cm2 and good friability of less than 0.7% indicates that they were hard and compact. The thickness of tablets was found to be within the limit of 4.020 + 0.32 mm and 4.350 + 0.05 mm.
The formulations conformed to the drug's content requirements for Amoxicillin: clavulanate present in them ranging from 2420.18% to 2580.04%, exhibiting appreciable uniformity of drug content. Thus, the physical properties of the prepared tablets are also found to be well controlled. The tablets were subjected to in vitro dissolution studies for 12 hours in various dissolution media (pH 1.2, 6.8, 7.4). The results of the study involving optimized formulation F5 indicated that at the end of 12 hours, the maximum drug release, 91.42 percent was attained. The results of the formulation release studies are shown in Table 4. Subsequently, formulation F5 was selected, coated with inner and outer coating materials, and then subjected to evaluation for further research. The coated formulations were evaluated for weight variation, thickness, hardness, friability, and drug content. The results of physicochemical evaluation of all batches of Amoxicillin: clavulanate coated matrix tablets are summarized in Table 5. The results of in-vitro drug release studies (Figure 3) carried out in different gastric and intestinal fluids indicated that the coated formulations were gastro resistant for 2 hours at pH 1.2 and for 3 hours at pH 7.4, with drug release being less than 10%.
Table 2: Result of pre-compression properties of Amoxicillin: clavulanate matrix tablets
|
Formulations |
Bulk Density (g/ml)* (± SD) |
Tapped Density (g/ml)* (± SD) |
Compressibility Index (%)* (± SD) |
Angle of Repose* (± SD) |
Hauser’s ratio |
|
F1 |
0.35±0.03 |
0.52±0.01 |
31.34±1.3 |
20.21±0.3 |
1.28±0.02 |
|
F2 |
0.32±0.01 |
0.57±0.02 |
44.52±0.3 |
22.87±0.1 |
1.29±0.02 |
|
F3 |
0.348±0.016 |
0.507±0.009 |
31.36±0.17 |
20.80±1.47 |
1.25±0.03 |
|
F4 |
0.313±0.020 |
0.565±0.005 |
44.60±0.26 |
24.22±0.46 |
1.10±0.09 |
|
F5 |
0.313±0.025 |
0.513±0.002 |
38.98±0.02 |
23.26±0.05 |
1.26±0.03 |
Table 3: Results of post compression properties of Amoxicillin: clavulanate matrix tablets
|
Formulation |
Thickness ± SD*(mm) |
Hardness (kg/cm2) ± SD* |
Friability (%) ± SD* |
Weight Uniformity (mg) ± SD* |
Uniformity of content ± SD* |
Swelling Index |
|
F1 |
4 .06±0.025 |
6.6±0.21 |
0.62±0.01 |
0.377±0.45 |
258±0.04 |
62.3 |
|
F2 |
4.35±0.05 |
5±0.48 |
0.66±0.25 |
0.378±0.24 |
242±0.18 |
59.4 |
|
F3 |
4 .12±0.12 |
5±0.02 |
0.64±0.54 |
0.378±0.63 |
248±0.02 |
54.2 |
|
F4 |
4.02±0.32 |
6±0.25 |
0.59±0.62 |
0.380±0.17 |
251±0.033 |
47.2 |
|
F5 |
4 .32±0.04 |
5±0.08 |
0.59±0.88 |
0.378±0.05 |
249±0.014 |
41.7 |
All value are mean ± SD, n=3
Table 4: In-vitro drug release data for formulation F1-F5
|
Time (hrs) |
% Drug Release |
||||
|
F1 |
F2 |
F3 |
F4 |
F5 |
|
|
1 |
7.33 |
8.8 |
9.0 |
9.43 |
10.81 |
|
2 |
12.46 |
11.7 |
16.22 |
19.86 |
21.53 |
|
3 |
16.70 |
16.8 |
21.6 |
28.82 |
29.62 |
|
4 |
21.32 |
22.5 |
28.54 |
32.41 |
34.60 |
|
5 |
24 |
26.41 |
34.66 |
38.55 |
40.34 |
|
6 |
26.2 |
29.11 |
39.70 |
45.20 |
48.91 |
|
7 |
30.2 |
32.8 |
45.90 |
49.87 |
55.40 |
|
8 |
35.42 |
36.92 |
48.13 |
53.61 |
62.53 |
|
9 |
38.1 |
42.53 |
51.93 |
58.33 |
74.33 |
|
10 |
41.55 |
46.88 |
54.47 |
66.28 |
82.58 |
|
11 |
45.21 |
51.64 |
59.33 |
71.54 |
86.22 |
|
12 |
46.39. |
54.76 |
62.11 |
75.87 |
91.42 |
Table 5: Evaluation of enteric coated tablets of mesalamine
|
Parameters |
E1 |
E2 |
E3 |
|
Hardness |
6.26±0.025 |
6.31±0.06 |
7.54±0.12 |
|
Thickness |
6.84±0.2 |
7.03±0.008 |
7.12±0.02 |
|
Friability |
0.58±0.6 |
0.56±1.12 |
0.54±0.44 |
|
Weight variation |
383±0.32 |
388±0.16 |
812±0.21 |
|
Disintegration time (min) (in pH 1.2) |
30 |
40 |
Not disintegrated |
|
Disintegration time (min) pH 6.8 |
4 |
7 |
10 |
Figure 3: in-vitro drug release studies of optimized coated tablet
The successful formulation of a pH-sensitive tablet for colon-specific amoxicillin-clavulanate was accomplished. The polymeric coating comprised of Eudragit L100 functioned to prevent drug release at both acidic and intestinal pH levels while allowing its release at pH level of ≥7 in the colon. Guar gum as matrix material contributed to the sustained action of the tablet. All in vitro studies conducted showed that the tablet successfully releases at the site of action and the total amount of released drug in the colon is very high. The various physicochemical properties of the tablet conform to the requirement as set by the pharmacopeial standards. The technique of wet granulation can be substituted with direct compression techniques, as it is easier, more efficient and more economical means of tableting. Several studies available prove that direct compression is the option in the tableting process. In vitro drug release experiments demonstrate that matrix tablets of guar gum can postpone the delivery of the active substance in the upper digestive tract, namely, stomach and small intestine. The formulation of mesalamine with the use of guar gum matrix tablets offers hope for future treatments of inflammatory bowel disease and other diseases of the colon. The next step includes conducting in-vivo and pharmacokinetic experiments as well.
1. Mishra AS, Ghosh B, Malliappan SP, Dutta G, Vasanthan M. Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems. RSC Adv. 2026; 16: 10022-10059. doi:10.1039/D5RA05194K.
2. Martínez E, Gamboa J, Finkielstein CV, Cańas AI, Osorio MA, Vélez Y, et al. Oral dosage forms for drug delivery to the colon: an existing gap between research and commercial applications. J Mater Sci Mater Med. 2025; 36: 24. doi:10.1007/s10856-025-06868-5.
3. Dedroog S, Ouyang J, Vaes E, Willemse F, Andersen SK, Van den Mooter G. Insight in the role of resistant starch and Eudragit S 100 in a coating for controlled release in the colonic region. Eur J Pharm Biopharm. 2025; 215: 114818. doi:10.1016/ j.ejpb.2025.114818.
4. Vemula SK, Narala S, et al. Quality by Design (QbD) approach to develop colon-specific ketoprofen hot-melt extruded pellets: impact of Eudragit® S 100 coating on the in vitro drug release. Pharmaceutics. 2024; 16(10): 1265. doi:10.3390/ pharmaceutics16101265.
5. Alshammari ND, Almotairy A, Almutairi M, Zhang P, Al Shawakri E, Vemula SK, et al. Colon-targeted 3D-printed mesalamine tablets: core-shell design and in vitro/ex-vivo evaluation. J Drug Deliv Sci Technol. 2024; 95: 105580. doi:10.1016/j.jddst.2024.105580.
6. Moutaharrik S, Maroni A, Neut C, Dubuquoy C, Dubuquoy L, Foppoli A, et al. In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release. Eur J Pharm Biopharm. 2023; 183: 13-23. doi:10.1016/ j.ejpb.2022.12.013.
7. Vemula SK, Daravath B, Gummadi SB, Repka MA. Formulation and development of flurbiprofen colon-specific Eudragit coated matrix tablets: use of a novel crude banana peel powder as a time-dependent polymer. AAPS PharmSciTech. 2023; 24: 189. doi:10.1208/s12249-023-02646-0.
8. Heikal EJ, Kaoud RM, Gad S, Mokhtar HI, Alattar A, Alshaman R, et al. Development of novel pH-sensitive Eudragit coated beads containing curcumin-mesalamine combination for colon-specific drug delivery. Gels. 2023; 9(4): 264. doi:10.3390/gels9040264.
9. Singh J, Nayak P. pH-responsive polymers for drug delivery: trends and opportunities. J Polym Sci. 2023; 61(22): 2828. doi:10.1002/pol.20230403.
10. Shaikh M, Desai N, Momin M, Bhatt LK. Formulation development and in-vitro/ex-vivo evaluation for a polysaccharide-based colon targeted matrix tablet. Curr Drug Deliv. 2021; 18(10): 1563-1573. doi:10.2174/1567201818666210708121739.
11. Coban O, Aytac Z, Yildiz ZI, Uyar T. Colon targeted delivery of niclosamide from β-cyclodextrin inclusion complex incorporated electrospun Eudragit® L100 nanofibers. Colloids Surf B Biointerfaces. 2021; 197: 111391. doi:10.1016/ j.colsurfb.2020.111391.
12. Joseph SK, Sabitha M, Nair SC. Stimuli-responsive polymeric nanosystem for colon specific drug delivery. Adv Pharm Bull. 2020; 10(1): 1-12. doi:10.15171/apb.2020.001.
13. Lee SH, Bajracharya R, Min JY, et al. Strategic approaches for colon targeted drug delivery: an overview of recent advancements. Pharmaceutics. 2020; 12(1): 68. doi:10.3390/ pharmaceutics12010068.
14. Chourey N, Chouksey K. Formulation and evaluation of enteric coated matrix tablets of mesalamine for inflammatory bowel disease. J Drug Deliv Ther. 2022; 12(1): 45-50. doi:10.22270/ jddt.v12i1.5176.
15. Hema Naga Durga D, Sowjanya TL, Pavani T, Duppala L. Formulation development and in-vitro evaluation of molsidomine matrix tablets for colon specific release. J Drug Deliv Ther. 2020; 10(2): 112-116. doi:10.22270/jddt.v10i2.3900.
16. Krishnaiah YSR, Satyanarayana S, Prasad YVR, Rama Prasad Y. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit® L100 and Eudragit S100 combinations. Drug Dev Ind Pharm. 2000; 26(5): 507-512. doi:10.1081/DDC-100101266.
17. Krishnaiah YSR, Satyanarayana S, Prasad YVR. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. Int J Pharm. 1999; 184(1): 1-7. doi:10.1016/S0378-5173(99)00097-3.
18. Bansal AK, Garg S. Design and evaluation of matrices of Eudragit with polycarbophil and carbopol for colon-specific delivery. J Drug Target. 2008; 16(10): 748-756. doi:10.1080/ 10611860802473345.
19. Mack I, et al. Insufficient stability of clavulanic acid in widely used child-appropriate formulations. Antibiotics (Basel). 2021; 10(2): 225. doi:10.3390/antibiotics10020225.
20. Wardrop J, Jaber AB, Ayres JW. Multiple-layer compression-coated tablets: formulation and humidity studies of novel chewable amoxicillin/clavulanate tablet formulations. Drug Dev Ind Pharm. 1998; 24(11): 1067-1071. doi:10.3109/03639049809082720.
21. Kukovetz W, et al. A new amoxicillin/clavulanate therapeutic system: preparation, in vitro and pharmacokinetic evaluation. Int J Pharm. 2007; 335(1-2): 106-113. doi:10.1016/ j.ijpharm.2006.11.007.
22. [Authors as indexed] An evaluation of amoxicillin/clavulanate stability in aqueous systems, including its suitability for outpatient parenteral antimicrobial therapy. Drug Des Devel Ther. 2024.
23. Sharma K, Kumar V, Kaith BS, Kumar V, Som S, Pandey A, et al. Evaluation of a conducting interpenetrating network based on gum ghatti-g-poly(acrylic acid-aniline) as a colon-specific delivery system for amoxicillin trihydrate and paracetamol. New J Chem. 2015; 39: 3021-3034. doi:10.1039/C4NJ01982B.
|
Received on 08.09.2026 Revised on 22.09.2026 Accepted on 05.10.2026 Published on 15.10.2026 Available online from October 24, 2026 Res. J. Pharma. Dosage Forms and Tech.2026; 18(4):318-324. DOI: 10.52711/0975-4377.2026.00044 ©AandV Publications All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License. |
|